Applied DNA Sciences, Inc.

Total revenues were $1.2 million in Q1 fiscal 2025, up from $891,000 in Q1 fiscal 2024. Operating loss was $3.0 million versus $3.8 million a year ago, adjusted EBITDA was negative $2.9 million versus negative $3.2 million, and net loss was $2.7 million versus $1.1 million in the prior year period. Cash and cash equivalents were $9.3 million at December 31, including approximately $5.7 million of net proceeds from the October offering and $509,000 from Series A warrant exercises; cash was $8.2 million at January 31 and average monthly cash burn was just over $1.2 million fiscal year to date. Management did not provide formal next-quarter or full-year revenue/EPS guidance; instead, it said fiscal 2025 is a year of execution for LineaRx, with GMP manufacturing for a Boston-based mRNA customer potentially starting in the May-June timeframe if development is completed, and Linea Donor DNA availability targeted for research use now with GMP availability later this calendar year.

James Hayward framed the quarter as a strategic reset, saying the restructuring is meant to rebuild shareholder value through a lower cost structure and a sharper focus on LineaRx. He said customer interest in Linea DNA and Linea IVT has exceeded expectations, the market is receptive to enzymatically produced DNA, and the company is now ready to deliver after validating its platform and certifying GMP Site One. His tone was confident and execution-focused, with repeated emphasis on LineaRx as the core growth engine.

Beth Jantzen said the company initiated a strategic restructuring in the quarter to bolster cash reserves, reduce burn, and support LineaRx, and that the DNA tagging/security segment is being exited with the wind-down expected by the end of the current quarter. She cited Q1 revenue of $1.2 million, operating loss of $3.0 million, net loss of $2.7 million, and adjusted EBITDA of negative $2.9 million, and explained that the operating loss improvement came mainly from lower SG&A, including lower stock-based compensation. On the balance sheet, she highlighted $9.3 million of cash and cash equivalents at December 31, $8.2 million at January 31, average monthly cash burn of just over $1.2 million, and a one-time charge of about $300,000 tied to the workforce reduction.

Analysts asked about the new Linea product opportunity versus IVT and CAR T, and Clay Shorrock said donor DNA is a logical extension of the same PCR-based workflow, with near-term focus on CAR T-like ex vivo gene editing rather than more mature mRNA markets. They also asked where revenue growth came from; management said it was primarily from a DNA tagging shipment for an existing cotton-marking customer and higher isotopic testing volume, with that cotton contract being retained post-restructuring. On the AML first-in-human trial, management said the phase one timeline is likely about eighteen months, revenue may not be large because it is hospital-based, but the real value is validation that linear DNA can be used in clinical settings and can offer a faster regulatory path than a plasmid competitor.